Efficacy of treatment of acute hepatiitis C in patients with HIV-infection

HIV Treat Bull - Vol. 7, No. 7/8, July/August 2006

In a paper in the 13 May edition of AIDS, Stephanie Dominguez and colleagues reported impressive responses to treatment of hepatitis C in a prospective pilot study of 25 consecutive HIV-positive men from two clinic in Paris, with acute HCV infection (documented seroconversion to HCV antibody or positive HCV RNA with negative PCR in previous 6 months). [1]

HCV was diagnosed due to clinical symptoms in 7 patients and following a rise in liver enzyme activity during routine HIV monitoring in 18 men.

At baseline, 23/25 patients were on HAART, with viral load <200 copies/mL: median CD4 count was 345 cells/mm³. Only one patient, with HCV genotype 3, spontaneously cleared HCV by week 12, with all other patients maintaining HCV RNA >50 copies/mL. Median time between acute HCV diagnosis and start of study was 14 weeks.

As four patients declined treatment and one patient was contraindicated for ribavirin therapy, 19/25 were treated with PEN interferon alpha-2a (180µg/week plus 800mg RBV/day) for 6 months, followed by 6 month follow-up.

The study reported sustained virological response (SVR) rates in 10/14 (71%) patients with evaluable data at 24 weeks after the end of HCV treatment. The authors reported that study treatment was well tolerated, with no change in CD4 cell count and concluded “early treatment of acute HCV infection with PegIFN alpha-2a and ribavirin for 24 weeks yields a high sustained virological response rate in HIV-infected patients”.

comment

In general, the cohort data for treatment of acute HCV infection in coinfected patients, are still evolving. Data from London (SVR) and Germany (EOT) indicate lower response rates 50-60% SVR, but these are still better than in chronic infection. As in HCV-monoinfection the optimal treatment strategy of PegIFN-monotherapy or PegIFN + RBV (800 mg or 1000-1200 mg) remains an open question.

Given the lower response rate in coinfected patients the role of RBV 1000 – 1200 mg/d should be assessed. Given the general low number of patients a cooperation of the cohorts for analysing and collecting the data would be a major advantage.

This paper was submitted for publication in November and accepted in January 2006, therefore the results from the full cohort should already be available and will hopefully be presented in Toronto. Nevertheless, these data support the recommendation for early treatment of acute HCV infection from the European Consensus Conference for coinfection last year. [2]

This highlights the clinical importance of diagnosing acute HCV - particularly in the UK where approximately 200 cases of sexual HCV infection has been reported in HIV-positive gay men in London and Brighton over the last few years. Routine HCV testing of gay men associated with higher risk for HCV infection (group sex, shared toys, recreational drug use, fisting, UAI, recent STI) is clearly important.

References

1. Dominguez S, Ghosn J, Valantin M-A et al, Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 20(8), 1157-1161 (12 May 2006)
2. Alberti A, Clumeck N, Collins S et al. Short Statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV coinfected patients. J Hepatol 2005; 42:615-624.

2008-03-10
IB060707-27

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.